Registry of patients who received oNKord® treatment
A Prospective Multicenter Observational Study to Assess Long-term Outcome of Participants Who Have Received oNKord®
This study is tracking patients with acute myeloid leukemia who have received oNKord® treatment to see how it affects their health over time.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 50 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Glycostem Therapeutics BV Industry-sponsored |
| Locations | 2 sites (Hanover and 1 other locations) |
| Trial ID | NCT05290662 on ClinicalTrials.gov |
What this trial studies
This observational registry study enrolls participants who have received at least one dose of oNKord®, which consists of allogeneic ex vivo-generated Natural Killer cells derived from umbilical cord blood. Participants from multiple previous clinical trials of oNKord® can be included, and their treatment history and clinical outcomes will be documented. After signing an informed consent form, participants will be followed for up to three years, with annual assessments of their medical status and any major clinical events. This study aims to gather comprehensive data on the long-term effects of oNKord® treatment in patients with acute myeloid leukemia (AML).
Who should consider this trial
Good fit: Ideal candidates are individuals who have received at least one dose of oNKord® in a clinical trial within the last three years.
Not a fit: Patients who have not received oNKord® or those who received it more than three years ago will not benefit from this registry.
Why it matters
Potential benefit: If successful, this registry could provide valuable insights into the long-term efficacy and safety of oNKord® for patients with AML.
How similar studies have performed: Other studies involving NK cell therapies have shown promising results, suggesting that this approach may be beneficial, although this specific registry is novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Receipt of at least one dose of oNKord® in a clinical trial * Participation must be within 3 years after the first infusion of oNKord® * Signature of ICF Exclusion Criteria: * N/A
Where this trial is running
Hanover and 1 other locations
- Medizinische Hochschule Hannover — Hanover, Germany (Recruiting)
- University Hospital Basel — Basel, Switzerland (Recruiting)
Study contacts
- Study coordinator: Katarzyna Nowek, PhD
- Email: medical@glycostem.com
- Phone: +31(0)412211001
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.